United Therapeutics Co. (NASDAQ:UTHR) CEO Sells $3,555,750.00 in Stock

United Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt sold 15,000 shares of the stock in a transaction on Friday, March 22nd. The shares were sold at an average price of $237.05, for a total transaction of $3,555,750.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares in the company, valued at $30,816.50. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink.

United Therapeutics Stock Down 1.9 %

Shares of NASDAQ:UTHR opened at $243.27 on Thursday. The company has a market cap of $11.45 billion, a price-to-earnings ratio of 12.26 and a beta of 0.52. The firm’s 50-day simple moving average is $225.55 and its 200-day simple moving average is $227.39. The company has a quick ratio of 4.28, a current ratio of 4.41 and a debt-to-equity ratio of 0.05. United Therapeutics Co. has a fifty-two week low of $204.44 and a fifty-two week high of $261.54.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, February 21st. The biotechnology company reported $4.36 earnings per share for the quarter, beating the consensus estimate of $4.28 by $0.08. The business had revenue of $614.70 million for the quarter, compared to the consensus estimate of $575.01 million. United Therapeutics had a net margin of 42.31% and a return on equity of 17.72%. The business’s quarterly revenue was up 25.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.67 earnings per share. As a group, equities research analysts predict that United Therapeutics Co. will post 23.32 earnings per share for the current year.

Institutional Trading of United Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Atlas Capital Advisors LLC acquired a new stake in shares of United Therapeutics in the fourth quarter valued at about $51,000. Northwestern Mutual Wealth Management Co. lifted its stake in shares of United Therapeutics by 49.6% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 196 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 65 shares during the period. GAMMA Investing LLC acquired a new stake in shares of United Therapeutics in the fourth quarter valued at about $43,000. Neo Ivy Capital Management acquired a new stake in shares of United Therapeutics in the second quarter valued at about $48,000. Finally, Zions Bancorporation N.A. acquired a new stake in shares of United Therapeutics in the first quarter valued at about $66,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on UTHR. StockNews.com downgraded shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. SVB Leerink began coverage on shares of United Therapeutics in a research report on Monday, February 5th. They issued an “outperform” rating and a $330.00 target price on the stock. Wedbush reaffirmed an “outperform” rating and issued a $308.00 target price on shares of United Therapeutics in a research report on Thursday, February 22nd. Leerink Partnrs reissued an “outperform” rating on shares of United Therapeutics in a research report on Monday, February 5th. Finally, HC Wainwright reissued a “buy” rating and set a $300.00 price objective on shares of United Therapeutics in a research report on Thursday, February 22nd. One investment analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $294.40.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.